斯基桑德林B是一种潜在的GLP-1R激动剂,通过刺激胰岛素分泌来发挥抗糖尿病作用
Jia Shang1, Wenhui Yan2, Xin Cui1
1Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, China; Institute of Cardiovascular Sciences, Translational Medicine Institute, Xi'an Jiaotong University, Xi'an, 710061, China.
Molecular and cellular endocrinology
|July 26, 2023
概括
小分子斯基桑德林B通过激活GLP-1受体通路,有效降低2型糖尿病患者的血糖,从而提供了潜在的新治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 药物发现 药物发现 药物发现
背景情况:
- 糖尿病是一种代谢障碍,其特征是高血糖.
- 目前的葡萄糖类-1受体激动剂 (GLP-1RA) 是宏分子,这带来了成本和便利性的挑战.
- 在2型糖尿病 (T2DM) 治疗中需要GLP-1RA的小分子替代品.
研究的目的:
- 为了识别与GLP-1受体 (GLP-1R) 结合的小分子.
- 为了确认已识别的小分子的激应活性.
- 在T2DM小鼠模型中评估一个有前途的候选者的治疗效果.
主要方法:
- 细胞膜染色学 (CMC) 和分子对接被用于选GLP-1R结合小分子.
- 在体外测试 (成像) 评估了胰岛素分泌和途径参与 (使用抑制剂).
- 在体内研究评估了在饮食/链毒素诱导的T2DM小鼠模型中施西桑德林B的疗效.
主要成果:
- 斯基桑德林B (Sch B) 被确定为具有强烈GLP-1R结合亲和力的小分子.
- 在体外,SchB通过GLP-1R/cAMP/PKA通路刺激胰岛素分泌.
- 在体内,Sch B改善了T2DM小鼠的血糖控制,葡萄糖耐受性和脂质概况.
结论:
- 斯基桑德林B作为GLP-1受体激动剂,缓解T2DM症状.
- Sch B通过GLP-1R/cAMP/PKA信号通路促进胰岛素的释放.
- 斯基桑德林B代表了对T2DM管理的潜在新型治疗剂.
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: Glinides
188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Oral Hypoglycemic Agents: Sulfonylureas
245
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
245


